Short answer
Biohaven Ltd. (BHVN) filed an 8-K current report with the SEC on August 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Item 2.02 section contains only an incorporation-by-reference disclaimer.
Biohaven Ltd. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Item 2.02 section contains only an incorporation-by-reference disclaimer
- No earnings figures, reporting period, or operating metrics provided in the supplied text
Item EX-99.1 · Exhibit EX-99.1
- Q2 2026 net loss narrowed to $137.3M, or $0.91/share, from $198.1M, reflecting lower development spending
- Cash, securities and restricted cash totaled approximately $270.5M, while notes payable reached $259.5M
- BHV-1300 entered Phase 3 for Graves’ disease after greater than 80% antibody reductions and rapid thyroid-hormone normalization
- BHV-1400 reduced pathogenic Gd-IgA1 greater than 60% within 48 hours, with pivotal IgA nephropathy testing targeted for 2H 2026
- Opakalim Phase 2/3 focal-epilepsy topline results remain expected in 2H 2026, creating a key near-term clinical catalyst
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Biohaven Ltd. 8-K filings
Get the next BHVN 8-K as it lands
Follow BHVN for push alerts, or ask the research agent what this filing means.